by Kai Herdin | Mar 31, 2026 | News
We are proud to announce that Dr. Keyue Sun and the Schlegel Lab have been selected as the inaugural recipients of the NADMED Award for their work on metabolic assessment of organ viability in transplantation. Their research tackles a critical question in transplant...
by Kai Herdin | Mar 18, 2026 | News
NADMED has partnered with London-based Altheome Labs to expand access to advanced NAD testing in the UK, marking another step in the company’s international growth. Through this collaboration, NADMED’s CE-marked NAD measurement technology will be integrated into...
by Kai Herdin | Feb 5, 2026 | News
A new abstract, presented at the American Stroke Association’s Conference, explores how NAD and NADP, critical molecules for cellular energy and repair, change in the early days after stroke and what that might mean for recovery. Preliminary findings (n=18) showed: •...
by Kai Herdin | Jan 4, 2026 | News
A study in Cell Reports Medicine shows significantly lower NAD+ levels in the brains of Alzheimer’s patients, especially in the parietal and occipital regions. The findings highlight a strong correlation between NAD+ depletion and mitochondrial dysfunction,...
by Kai Herdin | Nov 26, 2025 | News
A newly published study reveals that NAD⁺ can restore memory in Alzheimer’s disease models by correcting RNA splicing errors. This groundbreaking international research demonstrates how boosting this essential metabolic molecule improves memory and neuronal function...
by Kai Herdin | Sep 12, 2025 | News
NADMED has been selected to join the prestigious AMPlify program, a U.S. market entry initiative jointly organized by Mayo Clinic and Business Finland. The program combines world-class clinical expertise, valuable market knowledge, and extensive networks to support...